lecanemab Archives - Howard Gleckman

NIH Steps Back From Project Developing Alzheimer’s Diagnostic Standards

The National Institutes of Health’s Institute of Aging has dropped its name from a controversial joint project with Alzheimer’s Association to revise clinical research standards, which it calls criteria, for determining who has Alzheimer’s disease. The relationship was unusual. NIH rarely sponsors projects to develop such standards, and almost never partners with advocacy groups. Typically, such guidance is written by expert panels organized [...]

By Howard Gleckman|2023-10-31T17:27:50-04:00October 31st, 2023|dementia|0 Comments

The Biggest Barrier To New Anti-Alzheimer’s Drugs May Be Cost, Not Medicare Rules

The drug industry and its supporters are blasting the Centers for Medicare and Medicaid Services (CMS) for proposing to limit Medicare payments for the new anti-Alzheimer’s drug lecanemab to patients who participate in a trial or a special registry aimed at tracking their experience with the drug. CMS says the record-keeping will help provide important, real-world information about the benefits [...]

By Howard Gleckman|2023-06-14T12:12:06-04:00June 14th, 2023|dementia|0 Comments

Experts Raise New Questions About The Safety Of Anti-Alzheimer’s Drug Leqembi

Medical experts are raising new questions about the safety of the anti-Alzheimer’s drug lecanemab, which is marketed as Leqembi by drugmakers Biogen and Eisai. One study, which looked in detail at the death of a participant in a Leqembi research trial, suggests that people with a condition that affects as many as half of those with Alzheimer’s Disease may be [...]

By Howard Gleckman|2023-04-25T10:22:43-04:00April 25th, 2023|dementia|0 Comments

The FDA Approved The New Anti-Alzheimer’s Drug Leqembi. What You Need To Know

The FDA’s decision to grant accelerated approval for the anti-Alzheimer’s drug lecanemab, which will be sold as Leqembi, has significant potential for research into treatment of the disease. But people living with Alzheimer’s and their families will face difficult choices once the drug is made available later this month by Biogen and the Japanese firm Eisai. A trial found the [...]

By Howard Gleckman|2023-01-09T09:58:28-05:00January 9th, 2023|dementia, Uncategorized|0 Comments

What You Should Know About The Anti-Alzheimer’s Drug Lecanemab

What should people living with dementia and their families take away from the recent data published on lecanemab, the Alzheimer’s drug developed by Biogen and the Japanese firm Eisai? The drugmakers’ announcement of their Phase 3 trial results got lots of attention in the popular press. Some stories heralded the drug as a “breakthough.” But even experts disagree about the [...]

By Howard Gleckman|2022-12-08T11:13:27-05:00December 8th, 2022|dementia|0 Comments